SP JOFOC Adjuvant_Recombinant_Redacted.pdf

This notice publicizes a justification and approval for contract number 75A50120D00002 for the development and domestic manufacture of adjuvanted, recombinant pandemic influenza vaccines. Awarded to an unknown vendor by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the contract provides for an unknown amount and was awarded on December 5, 2019. The purpose of the justification and approval is to develop and domestically manufacture adjuvanted, recombinant pandemic influenza vaccines to strengthen pandemic preparedness and response capabilities in the United States.